Summary
35.69 0.71(2.03%)04/17/2025
Ultragenyx Pharmaceutical Inc. (RARE)
RARE reported last earnings on 2025-02-13 after the market. An EPS of $-1.39 was observed compared to an estimated EPS of $-1.32, resulting in a surprise value of $-0.07. A revenue of $165 million was observed compared to an estimated revenue of $159 million, resulting in a surprise value of $6 Million.
Ultragenyx Pharmaceutical Inc. (RARE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 2.03 | 4.54 | -9.96 | -10.78 | -37.13 | -19.09 | -43.44 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Fundamental Ratings
| Category | Rating |
| Main Rating | C |
| Recommended Rating | Sell |
| DCF | Buy |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 35.69 | |
| Open | 35.00 | |
| High | 35.74 | |
| Low | 34.74 | |
| Volume | 690,693 | |
| Change | 0.71 | |
| Change % | 2.03 | |
| Avg Volume (20 Days) | 967,468 | |
| Volume/Avg Volume (20 Days) Ratio | 0.71 | |
| 52 Week Range | 30.18 - 60.37 | |
| Price vs 52 Week High | -40.88% | |
| Price vs 52 Week Low | 18.26% | |
| Range | 0.00 | |
| Gap Up/Down | -0.15 | |
Profitibility | ||
| Market Capitalization (Mln) | 3,328 | |
| Revenue per share | 6.1878 | |
| Net Income per share | -6.2867 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -5.6771 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
04/16 09:49 EST - seekingalpha.com
Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline
Ultragenyx shows strong revenue growth and disciplined expense management, making it a compelling long-term investment despite inherent biotechnology risks. The company's diverse revenue streams from Crysvita, Dojolvi, and Evkeeza fund innovation and buffer against financial volatility. Key...
Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline
Ultragenyx shows strong revenue growth and disciplined expense management, making it a compelling long-term investment despite inherent biotechnology risks. The company's diverse revenue streams from Crysvita, Dojolvi, and Evkeeza fund innovation and buffer against financial volatility. Key...
04/10 10:30 EST - zacks.com
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
04/09 12:46 EST - globenewswire.com
BROAD ARROW ADDS RARE RUF CTR YELLOWBIRD TO PORSCHE AUCTION IN PARTNERSHIP WITH AIR|WATER
Broad Arrow Auctions, a Hagerty (NYSE: HGTY) company, has announced an exceedingly rare 1989 RUF CTR Yellowbird, chassis no. W09BT0348KPR06023, to lead its second annual Porsche Auction in partnership with Air|Water. Set for April 26 at the Orange County Fairgrounds in Costa Mesa, California, the...
BROAD ARROW ADDS RARE RUF CTR YELLOWBIRD TO PORSCHE AUCTION IN PARTNERSHIP WITH AIR|WATER
Broad Arrow Auctions, a Hagerty (NYSE: HGTY) company, has announced an exceedingly rare 1989 RUF CTR Yellowbird, chassis no. W09BT0348KPR06023, to lead its second annual Porsche Auction in partnership with Air|Water. Set for April 26 at the Orange County Fairgrounds in Costa Mesa, California, the...
03/19 17:00 EST - globenewswire.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 21,806 restricted stock units of the...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 21,806 restricted stock units of the...
02/24 16:30 EST - globenewswire.com
Ultragenyx to Participate at Investor Conferences in March
NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor...
Ultragenyx to Participate at Investor Conferences in March
NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor...
02/18 03:01 EST - globenewswire.com
AMERICAN SALARS ACQUIRES 18,083 HECTARE BRAZIL HARDROCK LCT PEGMATITE PROPERTY WITH RECENT SAMPLING UP TO 3.72% LI20 AND SIGNIFICANT RARE EARTHÂ ELEMENTÂ VALUES
VANCOUVER, BC, Feb. 18, 2025 (GLOBE NEWSWIRE) -- AMERICAN SALARS LITHIUM INC. ("AMERICAN SALARS" OR THE "COMPANY") (CSE: USLI, OTC: USLIF, FWB: Z3P, WKN:Â A3E2NY ) announces that it has entered into a share purchase agreement to acquire all of the outstanding shares of 1447377 BC Ltd. (the...
AMERICAN SALARS ACQUIRES 18,083 HECTARE BRAZIL HARDROCK LCT PEGMATITE PROPERTY WITH RECENT SAMPLING UP TO 3.72% LI20 AND SIGNIFICANT RARE EARTHÂ ELEMENTÂ VALUES
VANCOUVER, BC, Feb. 18, 2025 (GLOBE NEWSWIRE) -- AMERICAN SALARS LITHIUM INC. ("AMERICAN SALARS" OR THE "COMPANY") (CSE: USLI, OTC: USLIF, FWB: Z3P, WKN:Â A3E2NY ) announces that it has entered into a share purchase agreement to acquire all of the outstanding shares of 1447377 BC Ltd. (the...
02/14 10:41 EST - zacks.com
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
02/13 21:53 EST - seekingalpha.com
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO Howard Horn - CFO Eric Crombez - CMO Conference Call Participants Tazeen Ahmad - Bank of America...
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO Howard Horn - CFO Eric Crombez - CMO Conference Call Participants Tazeen Ahmad - Bank of America...
02/13 18:30 EST - zacks.com
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
02/13 18:11 EST - zacks.com
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.52 per share a year ago.
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
Ultragenyx (RARE) came out with a quarterly loss of $1.39 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.52 per share a year ago.
02/13 16:01 EST - globenewswire.com
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
2024 Total Revenue of $560 million, exceeding guidance Crysvita® revenue of $410 million and Dojolvi® revenue of $88 million
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
2024 Total Revenue of $560 million, exceeding guidance Crysvita® revenue of $410 million and Dojolvi® revenue of $88 million
02/06 16:30 EST - globenewswire.com
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at...
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at...
02/06 11:31 EST - zacks.com
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study
Ultragenyx announces new safety and efficacy data from its pivotal study of its investigational candidate, UX111, for patients with Sanfilippo syndrome type A.
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study
Ultragenyx announces new safety and efficacy data from its pivotal study of its investigational candidate, UX111, for patients with Sanfilippo syndrome type A.
02/05 08:00 EST - globenewswire.com
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS
Modified intent-to-treat group demonstrated +22.7 point (p
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS
Modified intent-to-treat group demonstrated +22.7 point (p
01/15 14:05 EST - benzinga.com
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
In conjunction with the 2025 J.P. Morgan Healthcare Conference, the analyst hosted an investor lunch with Ultragenyx Pharmaceutical Inc RARE.
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
In conjunction with the 2025 J.P. Morgan Healthcare Conference, the analyst hosted an investor lunch with Ultragenyx Pharmaceutical Inc RARE.
01/12 11:00 EST - globenewswire.com
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $89 million
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $89 million
01/07 11:25 EST - zacks.com
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder.
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder.
01/06 16:30 EST - globenewswire.com
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the...
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the...